Nature's Weapons: How Natural Plant Compounds May Help Fight Cancer

Table of Contents

• Key Points
• Background: Why Natural Compounds Matter in Cancer Research
• What Are Chemopreventive Agents and How Do They Work?
• Phytochemicals and Cancer: The Science Behind Plant-Based Treatments
• Curcumin: The Golden Spice Compound
• Apigenin: A Promising Compound from Fruits and Vegetables
• Clinical Implications: What This Means for Patients
• Limitations and Challenges
• Recommendations and Future Directions
• Frequently Asked Questions
• Source Information

Key Points

• Curcumin combined with piperine increased curcumin bioavailability by 125% in rats and 2000% in humans in one pharmacokinetic study.
• In a 30-patient breast cancer trial, curcumin reduced severe radiation-induced dermatitis compared to placebo.
• In a cervical cancer trial, curcumin before radiation reduced serum survivin in 75% of patients versus 40% with placebo.
• Apigenin reprogrammed alternative splicing in triple-negative breast cancer cells and mouse models, reducing proliferation and increasing pro-apoptotic isoforms.
• Natural compounds show low toxicity and wide availability but poor bioavailability limits their effectiveness without improved delivery systems.

Background: Why Natural Compounds Matter in Cancer Research

Cancer remains one of the most significant health challenges worldwide. This reality drives scientists to search continuously for new and better treatment strategies. Natural compounds derived from plants have emerged as promising candidates for both preventing cancer and treating it.

The roots of this research go back thousands of years. Ayurveda, a healing science that originated in India approximately 5,000 years ago, first introduced the concept of using natural ingredients for health purposes. These ingredients include curcumin, quercetin, piperine, and resveratrol. Most of these Ayurvedic bioactive compounds (ABCs) come from different parts of herbs, shrubs, and plants.

Scientists can categorize these natural compounds into several chemical types:

• Phenols and polyphenols
• Terpenoids
• Thiols
• Dietary fiber
• Flavonoids
• Anthocyanidins
• Phenolic acids
• Curcuminoids
• Alkaloids
• Carbohydrates
• Carotenoids
• Vitamins
• Phytosterols
• Polyunsaturated lipids
• Organosulfur compounds

These compounds demonstrate a wide range of pharmacological properties. They act as antioxidants, reduce inflammation, fight bacteria, modulate the immune system, and show anticancer, anti-proliferative, antimutagenic, and antithrombotic activities. This makes them valuable for both nutraceuticals (food products with health benefits) and pharmaceutical treatments.

However, using these compounds in complex foods presents challenges. They are sensitive to various factors such as pH and temperature. This sensitivity makes comprehensive research difficult because scientists need specialized extraction and separation techniques to identify and characterize these compounds.

Understanding How Cancer Develops

Cancer development, also called carcinogenesis or oncogenesis, is a multistep process. Genetic and environmental factors must come together for normal cells to transform into cancer cells and escape programmed cell death (apoptosis).

The first stage of cancer development begins with multiple irreversible genetic mutations. These mutations cause deregulation of cell cycle control. This promotes selective growth of the initial cells and their offspring by enhancing mitogenic signaling (signals that promote cell division). Eventually, uncontrolled cellular proliferation begins to spread and invade tissues locally or at distant sites.

Inflammation is a natural response by the body's immune system against injury, infection, and tumor cells. Cytokines and chemokines (signaling molecules) play crucial roles as regulators of inflammatory signaling in tumor promotion. Clinical trials investigating anti-cytokine and anti-chemokine receptor therapies have shown promising effects.

Current research in cancer therapy focuses on the increase of immune cell infiltration in the tumor microenvironment (TME) and how these cells interact with surrounding tissue and tumor cells. Cancer-associated inflammation has chronological aspects that scientists explain in three ways:

1. Autoimmunity (the immune system attacking the body's own tissues)
2. Cancer therapy-induced inflammation
3. Tumor-induced inflammation

Single cell transcriptomics (a technique that analyzes gene activity in individual cells) has revealed that tumor-associated fibroblasts and immune cells increase pro-tumorigenic inflammation. This understanding has led to promising therapy developments, including cancer vaccines, bi-specific anti-PDL1 antibodies, and T cells engineered with chimeric antigen receptors (CARs).

The master regulator NF-κB signaling pathway mediates proinflammatory factors including IL-1α, IL-1β, IL-6, TNF-α, CXCL-1, and CXCL-2. These factors promote cell proliferation through STAT3-mediated activation of the MCL-1 oncogene (a cancer-promoting gene). The TNF cytokine family members TNFα, TNF-β, and IL-1 cytokines in the tumor microenvironment constitutively activate transcription factors NF-κB, AP1 (JUN/FOS), and STAT3. This activation supports oncogenic pathways.

Therefore, NF-κB-initiated proinflammatory signaling has a pivotal function in the onset and advancement of cancer through immune dysregulation and oncogene expression in cancer stem cells. This inflammatory feedback loop contributes to drug resistance in breast cancer and establishes autocrine and paracrine regulation of mitogens in the tumor microenvironment.

Transforming growth factor β (TGF-β) is secreted by tumor cells and is considered a multipotent cytokine. It influences the tumor microenvironment by inducing vascularization (blood vessel formation), causing strong immunosuppression in T and NK cells, and promoting tumor progression to mesenchymal transition through SMAD pathway activation.

What Are Chemopreventive Agents and How Do They Work?

Chemopreventive agents are substances that help prevent cancer or slow its progression. In contrast, chemotherapeutic agents are used after a confirmed cancer diagnosis. These agents can be natural or synthetic and work through various mechanisms.

Chemopreventive agents protect DNA from reactive oxygen species (ROS)-induced damage, inhibit cell proliferation, and promote apoptosis (programmed cell death) in cancer cells. Scientists classify these agents into three types based on the stage at which they act during cancer development:

• Primary agents: These compounds inhibit the genotoxic effects of carcinogens at the pre-cancerous stage.
• Secondary agents: These block the development of a malignant phenotype. Preventive cancer diagnoses, such as screening through mammography in high-risk female populations or colonoscopy for colorectal cancers, are considered risk-reducing secondary preventive strategies.
• Tertiary agents: These prevent cancer recurrence after successful therapeutic or surgical management of tumors.

Tamoxifen, a selective estrogen receptor modulator, was the first drug approved by the FDA to reduce ER-positive breast cancer among high-risk populations. Other agents used in clinical practice include:

• Metformin (a diabetes drug with potential cancer-preventive effects)
• Statin drugs (which inhibit RhoA/Rho kinase and Ras/ERK pathways)
• Aspirin (a selective COX-2 inhibitor classified as a nonsteroidal anti-inflammatory drug, or NSAID)
• IL-1 cytokine inhibitors

Viral vaccines for BV and HPV are the best examples of immunoprevention against transformation by viral infection. These preventive vaccines have been introduced in national immunization programs of developed countries.

The Promise of Phytochemicals

Phytochemicals, naturally occurring compounds found in plants, have gained attention as potential chemopreventive agents. They exhibit anti-cancer properties by modulating inflammatory, hormonal, cell division, and redox homeostasis signaling pathways. This modulation induces apoptosis and inhibits tumor growth.

However, chemical chemotherapeutic agents, while effective in treating cancer, can have limitations and side effects. These include toxicity to normal cells, development of drug resistance, and adverse effects on the immune system. Phytochemicals have demonstrated potential for anti-inflammatory effects by regulating the canonical pathways involved in inflammation.

Many active compounds possess protective properties against side effects of cancer therapies when combined with chemotherapeutic drugs. Isothiocyanates and curcumin are highlighted as natural phytochemicals with significant anti-inflammatory and cancer chemopreventive effects. Scientists have been focusing on improving therapy results by applying precision medicine and specifically targeting tumors with personalized medicine, combining chemotherapeutic side effect-alleviating drugs and natural compounds.

Phytochemicals and Cancer: The Science Behind Plant-Based Treatments

Several Ayurvedic bioactive compounds have shown potential anti-cancer effects by regulating molecular pathways implicated in the growth and progression of cancer. These mechanisms include:

• Increasing antioxidant potential
• Inhibiting proliferation (uncontrolled cell growth)
• Inducing cell cycle arrest and apoptosis
• Regulating the immune system

Any plausible drug candidate is studied for its physicochemical and pharmacokinetic characteristics (how the body absorbs, distributes, metabolizes, and excretes the drug). This review discusses the biochemical propensity and various biological properties of active phytochemicals such as curcumin, resveratrol, apigenin, quercetin, and piperine.

Understanding Absorption and Brain Penetration

Scientists use a predictive model called the BOILED-Egg plot to assess how well compounds are absorbed. This graph, generated on SwissADME (a web tool for predicting drug properties), allows probabilistic assessment of passive gastrointestinal absorption (HIA) and brain permeability (BBB).

The model relates the positioning of molecules to the water partition coefficient (WLOGP) and topological polar surface area (TPSA). Molecules within the white area are predicted to have a high probability of passive absorption through the gastrointestinal tract. Those within the yellow region (yolk) are expected to have a high likelihood of crossing the blood-brain barrier.

The white and yellow regions do not exclude each other. This means that all molecules in the yolk region are equally permissible through gastrointestinal absorption, but not inversely. Blue points indicate molecules predicted to be actively effluxed by P-glycoprotein (PGP+), while red points signify those predicted as non-substrates of P-glycoprotein (PGP−).

The five substances discussed in this review are PGP-negative, suggesting their intracellular accumulation. The blood-brain barrier consists of a monolayer of endothelial cells associated with astrocytes and pericytes. This lining forms a selective filtering barrier that prevents the passage of large molecules, heavy metals, drug compounds, and pesticides to protect the nervous system from toxic and infectious agents.

The blood-brain barrier remains a major obstacle to treating neurological degenerative and proliferative diseases due to selective passage and lack of proinflammatory activity. Piperine and resveratrol are predicted candidates for blood-brain barrier permeation.

Curcumin: The Golden Spice Compound

Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] is a lipophilic (fat-soluble) flavonoid compound found in the rhizome of Curcuma longa, commonly known as turmeric. Chemically, curcumin is composed of two oxy-substituted aryl groups flanking a seven-carbon chain. This structure participates in biological redox reactions, giving antioxidant capacity to stressed cells.

In in vivo (living organism) experiments, curcumin has shown potent antioxidant, anti-inflammatory, neuroprotective, and antitumor properties. It achieves these effects by activating nuclear factor erythroid 2-related factor 2 (Nrf2)-driven pathways.

The Bioavailability Challenge

Poor bioavailability (the proportion of a substance that enters circulation when introduced into the body) limits curcumin's potential therapeutic use in clinical settings. However, studies on various curcumin derivatives, analogues, nano-carriers, and combination formulas are gaining attention to improve curcumin bioavailability.

Curcumin and its analogues possess pathway-modulating potential by binding to various cellular proteins, receptors, and channels. They bind through covalent, non-covalent hydrophilic, or hydrogen bonding. Studies reveal that TNF-α, Cox-1, Cox-2, Bcl-2, HDAC, DNMT-1, and HIV-1 integrase protein are some binding partners of curcumin.

Compounds like resveratrol, piperine, catechins, quercetin, and genistein in combination have been reported to be synergistic with curcumin's action of alleviating inflammation. The therapeutic effects of curcumin are blunted because of two main factors:

1. Low water solubility
2. Faster metabolism and elimination from the system

A pharmacokinetic study reports that the serum bioavailability of curcumin in rats and humans was enhanced by 125% and 2000% respectively when administered in combination with piperine. Piperine enhances intestinal absorption, serum concentration, and bioavailability of curcumin.

Curcumin and Brain Health

Studies report that despite having poor blood-brain barrier crossing properties, this does not limit curcumin's therapeutic effects on neuronal diseases. Curcumin present in essential oils has been demonstrated to penetrate the blood-brain barrier. Curcumin present in essential oils exerts a protective effect against aluminum chloride (AlCl₃)-induced neurotoxicity in the brains of Swiss albino mice. The turmeric extract in essential oils improved curcumin bioavailability by more than 10-fold compared to curcumin without essential oils.

A formulation of curcumin derivatives dispersed in a phospholipid matrix was given to 19 patients with Parkinson's disease. Patients in the treatment arm showed detectable curcumin in cerebrospinal fluid (CSF) and reduced phosphorylated α-synuclein (p-syn) load in neurons of a skin biopsy. Moreover, the curcuminoid-treated group showed a decrease of COMPASS-31 and NMSS scores (clinical assessment scales), and improved clinical parameters compared to untreated patients.

Curcumin and the Nrf2 Pathway

Recent studies emphasize the significance of Nrf2 (nuclear factor-erythroid 2-related factor 2) as a crucial transcription factor in defending against inflammation, oxidative stress, and electrophilic stress. Research with diverse animal models has shown that Nrf2 deficiency heightens susceptibility to various cancers, suggesting its role as a tumor suppressor in preclinical models. Conversely, hyperactivated Nrf2 has been linked to several tumors and unfavorable prognoses.

The zinc-curcumin compound, Zn(II)-curc, has demonstrated the ability to activate Nrf2, exhibiting anticancer effects in various cancer cell lines. This compound increases levels of heme oxygenase-1 (HO-1), p62/SQSTM1, and Nrf2 while decreasing the Nrf2 inhibitor Keap1. The interaction between p62/SQSTM1 and Nrf2 may increase treatment effectiveness.

Additionally, the anti-inflammatory and antioxidative characteristics of curcumin are linked to its modulation of the Nrf2 pathway. This modulation enhances antioxidant pathways and glutathione production while improving insulin resistance.

Curcumin Combined with Chemotherapy

Cisplatin is a primary chemotherapeutic drug used against many cancers due to its cytotoxic action of inhibiting DNA transcription and replication in actively proliferating cells. However, it confers off-target effects as multi-organ toxicity makes this drug less useful in cancer treatment. The combination therapy approach with natural compounds has given new hope to minimize side effects and improve the efficacy of chemotherapeutic drugs.

The co-treatment of cisplatin with curcumin induced apoptosis by activating NRF2 and inhibited ovarian cancer plasticity marker endothelin-1 (ET-1) in SKOV3 cells as well as in a rat model. The study showed curcumin treatment improved the expression of PGC-1α and TFAM (mitochondrial biogenesis markers) and prevented renal fibrosis.

Patients with high NCL and PD-L1 expressing triple-negative breast cancer (TNBC) showed faster cancer progression and poor outcomes. An in vitro study examined NCLHigh/PD-L1High MDA-MB-231 and NCLHigh/PD-L1High HCC70 TNBC cells treated with curcumin. Results showed downregulation of PD-L1 expression and effective cytotoxic activity by NCL-specific T cells. Curcumin has been found to stimulate intracellular autophagy (the body's way of clearing damaged cells).

Curcumin and Drug Resistance

Curcumin is renowned for its anti-inflammatory attributes shown by inhibiting the proinflammatory cytokine-activated JAK/STAT3 pathway. In a study involving tumor-associated fibroblasts (TAF) from gastric cancer in vitro, co-culturing and mouse xenograft induced the chemo-resistant gastric cancer phenotype. Curcumin treatment abrogated the chemoresistance by strongly suppressing IL-6 and IL-8 expression in co-cultured CAF by suppressing the JAK/STAT3 pathway.

Clinical Trials with Curcumin

A clinical trial employing a randomized, double-blind, placebo-controlled design was conducted to investigate the potential of curcumin in mitigating severe dermatitis induced by radiation therapy among 30 breast cancer patients. The curcumin treatment alleviated severe radiation-induced dermatitis at the end of the trial compared to the placebo.

Tumor necrosis factor-α (TNF-α) is a pivotal inflammatory mediator in the tumor microenvironment and is on the radar of many anti-inflammatory and anti-cancer treatments. A meta-analysis published on eight randomized controlled trials on patients subjected to curcumin supplementation as intervention showed significant reduction in circulating TNF-α.

A separate randomized controlled trial involved patients with stage IIB-IIIB cervical carcinoma. Curcumin intervention before radiation therapy induced radio-sensitization and better therapy outcome by reducing serum survivin protein levels in 75% of patients. In contrast, 60% of patients in the placebo arm found elevated serum survivin protein.

Apigenin: A Promising Compound from Fruits and Vegetables

Apigenin is derived naturally from a variety of fruits, vegetables, and Chinese medicinal herbs. It has been extensively studied for its potential anti-cancer effects and low toxicity. Studies indicate that apigenin exhibits suppressive effects on various human cancers both in laboratory settings and in living organisms.

Apigenin achieves these effects through a range of biological mechanisms:

• Initiation of cell apoptosis and autophagy
• Induction of cell cycle arrest
• Inhibition of cell migration and invasion
• Promotion of an immune response

Studies report that apigenin modulates several cell signaling pathways, including PI3K/AKT, MAPK/ERK, JAK/STAT, NF-κB, and Wnt/β-catenin pathways. Moreover, apigenin has been extensively researched for its potential in cancer prevention and treatment. Apigenin influences various cellular processes such as tumor suppression, angiogenesis (blood vessel formation), apoptosis, cell cycle regulation, and inflammation.

Apigenin and Breast Cancer

Epidemiological research highlights that the introduction of natural substances into the diet can slow down the development of tumors, especially female tumors such as cervical, ovarian, and breast cancer. Zhang et al. Research was conducted investigating the anti-tumor impact of apigenin on breast cancer. The research examined apigenin's effects both in laboratory settings using 4T1 cells and in living organisms on a xenografted tumor mouse model.

The study revealed that apigenin triggers apoptosis in breast cancer cells through modulation of the PI3K/AKT/Nrf2 pathway. Additionally, apigenin has been shown to enhance the immune microenvironment of tumors in mice afflicted with breast tumors, ultimately suppressing breast cancer growth. As a result, apigenin emerges as a hopeful option for breast cancer treatment.

Apigenin and Triple-Negative Breast Cancer

Alternative splicing (AS) plays a crucial role in the diversification of cancer-specific transcriptomes (the complete set of RNA molecules in cells). Triple-negative breast cancer (TNBC) is known for its resilience against cancer-specific transcriptome modifications. Aberrant splicing isoforms of the TNBC transcriptome promote tumor development and resistance.

In this context, identifying strategies to reprogram alternative splicing circuits toward transcriptomes that delay tumor growth and improve therapy response becomes fundamental. Apigenin, linked with splicing factors like heterogeneous nuclear ribonucleoprotein A2 (hnRNPA2), has the ability to reshape the alternative splicing transcriptome associated with TNBC.

Notably, apigenin-mediated alternative splicing events were found to be significantly enriched in substrates of hnRNPA2. Through comparative transcriptomic analyses of human TNBC tumors and non-tumorous tissues, researchers highlighted that apigenin contributes to shifting the alternative splicing isoforms (ASI) associated with cancer toward non-tumorous ones. This shift shows a preference for anti-apoptotic and cell proliferation factors.

In vivo, in TNBC xenografted mice, apigenin altered cancer-associated aberrant alternative splicing isoforms, reducing cell proliferation and increasing pro-apoptotic alternative splicing isoforms.

Improving Apigenin Delivery

Conventional anti-tumor therapies in most cases lead to adverse effects and are sometimes not effective. Often the anticancer properties of natural substances such as apigenin are slowed down by their low solubility in water. For this reason, nanostructured lipid carriers (NLCs) encapsulating apigenin (APG-NLC) with a lipid matrix containing rosehip oil have been developed. Rosehip oil is known for its anti-inflammatory and antioxidant properties.

APG-NLC was optimized, achieving an average particle size of less than 200 nm, a surface charge of −20 mV, and an encapsulation efficiency of more than 99%. In vitro studies demonstrated significant antiangiogenic activity of APG-NLC in ovo (in eggs) and selective antiproliferative effects on various tumor cell lines, without inducing toxicity in healthy cells.

Yang et al. utilized a copolymer commonly used in drug delivery, Poly (lactic-co-glycolic acid) (PLGA), along with hyaluronic acid (HA) to prepare HA-coated PLGA nanoparticles. These nanoparticles are specific for CD44 receptors on colon cancer cells with high CD44 expression.

Apigenin was encapsulated in PLGA to create PLGA-API-NPs, which were subsequently coated first with chitosan and then with HA. This resulted in HA-PLGA-API-NPs, which showed a stronger and more prolonged release ability. These nanoparticles have demonstrated efficacy as a drug delivery system for apigenin in treating colon tumors with high CD44 expression. Specifically, in nude mice, HA-PLGA-API-NPs exhibited enhanced targeting precision for the HT-29 ectopic tumor model compared to PLGA-API-NPs.

Clinical Implications: What This Means for Patients

The exploration of natural compounds as cancer therapeutics offers several advantages for patients. These advantages include low toxicity, wide availability, and compatibility with conventional chemotherapeutic agents.

The research highlights that natural compounds can work in several ways to help patients:

• Antioxidant activity: These compounds protect cells from damage caused by reactive oxygen species.
• Immunomodulatory effects: They help regulate and strengthen the immune system's ability to fight cancer.
• Anti-carcinogenic properties: They can prevent or slow the development of cancer.
• Chemo-sensitizing effects: They can make cancer cells more responsive to chemotherapy drugs.

For patients undergoing cancer treatment, the combination of natural compounds with conventional therapies may offer benefits. Curcumin has been shown to reduce severe radiation-induced dermatitis in breast cancer patients. It has also demonstrated the ability to reduce circulating TNF-α, a key inflammatory mediator.

In cervical carcinoma patients, curcumin intervention before radiation therapy induced radio-sensitization and better therapy outcomes. This was measured by reducing serum survivin protein levels in 75% of patients, compared to only 40% in the placebo group showing reduced levels.

Innovative delivery systems and personalized treatment approaches may further enhance the bioavailability and therapeutic utility of these compounds. This creates a synergistic approach with chemo- and radiotherapeutic disease management.

Limitations and Challenges

Despite promising findings, several limitations affect the use of natural compounds in cancer treatment. The most significant challenge is poor bioavailability. Curcumin, for example, has low water solubility and is rapidly metabolized and eliminated from the body.

The use of these compounds in complex foods is limited because they are sensitive to various factors such as pH and temperature. Comprehensive research on identification and characterization of these compounds can be challenging due to their chemical diversity and the need for extraction and separation techniques.

The blood-brain barrier remains a major obstacle to treating neurological degenerative and proliferative diseases. This barrier prevents the passage of large molecules, heavy metals, drug compounds, and pesticides to protect the nervous system. While piperine and resveratrol are predicted candidates for blood-brain barrier permeation, other compounds like curcumin have poor blood-brain barrier crossing properties.

Chemical chemotherapeutic agents, while effective in treating cancer, can have limitations and side effects. These include toxicity to normal cells, development of drug resistance, and adverse effects on the immune system. The challenge remains to find the optimal balance between therapeutic efficacy and safety.

Recommendations and Future Directions

The review underscores the importance of natural compounds in cancer prevention and treatment. It promotes a multidisciplinary approach to the development of innovative therapeutic strategies.

Based on the findings, several recommendations emerge for advancing this field:

1. Develop improved delivery systems: Nanostructured lipid carriers and nanoparticle formulations show promise for enhancing bioavailability and targeted delivery of natural compounds.
2. Conduct more clinical trials: While preclinical evidence is promising, more human studies are needed to confirm efficacy and safety.
3. Explore combination therapies: Combining natural compounds with conventional chemotherapeutic agents may reduce side effects and improve outcomes.
4. Apply personalized medicine approaches: Precision medicine and specifically targeting tumors with personalized medicine may improve therapy results.
5. Investigate synergistic combinations: Compounds like resveratrol, piperine, catechins, quercetin, and genistein in combination have been reported to be synergistic with curcumin's action.

Scientists have been focusing on improving therapy results by applying precision medicine and specifically targeting tumors with personalized medicine. This approach combines chemotherapeutic side effect-alleviating drugs and natural compounds.

The current ongoing clinical trials continue to investigate the potential of these natural compounds. The research promotes a comprehensive understanding of their anticancer mechanisms and clinical applications for advancing personalized cancer care to improve patient outcomes.

For patients interested in natural compounds as part of their cancer care, it is essential to discuss these options with their healthcare team. While these compounds show promise, they should not replace conventional cancer treatments without medical supervision. The evidence supports their potential role as adjuvants (additions) to standard therapy rather than stand-alone treatments.

Frequently Asked Questions

Can natural plant compounds like curcumin or apigenin replace my standard cancer treatment?

No. The evidence supports their potential role as additions to standard therapy, not as stand-alone treatments. They should not replace conventional cancer treatments without medical supervision. Patients interested in these compounds should discuss them with their healthcare team, as research suggests they may work alongside chemotherapy or radiation rather than instead of it.

What did the clinical trial of curcumin for radiation-induced dermatitis find?

In a randomized, double-blind, placebo-controlled trial of 30 breast cancer patients, curcumin treatment alleviated severe radiation-induced dermatitis at the end of the trial compared to placebo. This suggests curcumin may help reduce this side effect of radiation therapy, but the small size means further research is needed to confirm the finding.

How does piperine affect curcumin absorption?

A pharmacokinetic study found that giving curcumin with piperine increased its serum bioavailability by 125% in rats and 2000% in humans. Piperine enhances intestinal absorption and serum concentration of curcumin. This combination may help overcome curcumin's normally poor absorption, but it does not guarantee clinical benefit without further study.

What is the main limitation of using natural compounds like curcumin for cancer?

The most significant challenge is poor bioavailability. Curcumin, for example, has low water solubility and is rapidly metabolized and eliminated from the body. This limits its effectiveness without innovative delivery systems. Additionally, these compounds are sensitive to factors like pH and temperature, making research and formulation difficult.

What did the study of curcumin in cervical cancer patients receiving radiation show?

In a randomized controlled trial of patients with stage IIB-IIIB cervical carcinoma, curcumin taken before radiation therapy induced radio-sensitization and better therapy outcomes. It reduced serum survivin protein levels in 75% of patients, compared to 40% in the placebo group showing reduced levels. This suggests curcumin may improve radiation response in this specific group.

Can apigenin help treat triple-negative breast cancer?

In laboratory and mouse studies, apigenin altered cancer-associated alternative splicing isoforms in triple-negative breast cancer, reducing cell proliferation and increasing pro-apoptotic isoforms. It also enhanced the immune microenvironment in mice with breast tumors. However, these are preclinical findings; human trials are needed to confirm any benefit for patients.

Are there any natural compounds that can cross the blood-brain barrier?

Piperine and resveratrol are predicted candidates for blood-brain barrier permeation, according to a predictive model. Curcumin has poor blood-brain barrier crossing properties, though curcumin in essential oils has been shown to penetrate it. The blood-brain barrier remains a major obstacle for treating neurological diseases with most compounds.

I have triple-negative breast cancer and I'm considering adding natural compounds like curcumin or apigenin to my treatment — when should I get a second opinion?

A second opinion is worth seeking before adding any natural compound to standard therapy. Curcumin has been shown to enhance chemotherapy effects and reduce radiation-induced dermatitis, and apigenin can reprogram cancer cell behavior in triple-negative breast cancer, but these compounds have poor absorption and should not replace conventional treatment without medical supervision. An independent review can confirm whether a compound is appropriate alongside your specific regimen, since interactions and delivery matter. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: Nature's weapons: Bioactive compounds as anti-cancer agents.

Journal: AIMS public health

DOI: 10.3934/publichealth.2024038

License: CC BY (open access)

Authors: Auti A, Tathode M, Marino MM, Vitiello A, Ballini A, Miele F, Mazzone V, Ambrosino A, Boccellino M.

Publication: AIMS Public Health, Volume 11, Issue 3, pages 747–772

DOI: 10.3934/publichealth.2024038

Publication Dates: Received February 29, 2024; Revised April 23, 2024; Accepted April 28, 2024; Published June 18, 2024

Author Affiliations: Department of Precision Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy; Ministry of Health, Directorate-General for Health Prevention, Rome, Italy; Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy; General Surgery Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy; Department of Experimental Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy; Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy

This patient-friendly article is based on peer-reviewed research. The original article is a comprehensive review of preclinical and clinical evidence regarding natural compounds in cancer prevention and therapy.